Cohen Capital Management Inc. Sells 200 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Cohen Capital Management Inc. cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,859 shares of the medical equipment provider’s stock after selling 200 shares during the period. Cohen Capital Management Inc.’s holdings in Zimmer Biomet were worth $3,577,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ZBH. Olympiad Research LP bought a new position in Zimmer Biomet in the 4th quarter worth about $228,000. Callan Capital LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $209,000. Camelot Portfolios LLC grew its stake in Zimmer Biomet by 15.7% in the fourth quarter. Camelot Portfolios LLC now owns 4,434 shares of the medical equipment provider’s stock worth $468,000 after purchasing an additional 601 shares in the last quarter. Advantage Trust Co purchased a new position in Zimmer Biomet during the 4th quarter worth $53,000. Finally, Eubel Brady & Suttman Asset Management Inc. raised its position in Zimmer Biomet by 1.4% during the 4th quarter. Eubel Brady & Suttman Asset Management Inc. now owns 233,456 shares of the medical equipment provider’s stock valued at $24,660,000 after purchasing an additional 3,128 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $104.89 on Friday. The company has a 50 day moving average price of $105.86 and a 200 day moving average price of $107.45. The firm has a market capitalization of $20.88 billion, a P/E ratio of 23.57, a PEG ratio of 1.95 and a beta of 1.02. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the company earned $2.20 earnings per share. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.92%. Zimmer Biomet’s payout ratio is presently 21.57%.

Analysts Set New Price Targets

ZBH has been the topic of a number of recent research reports. Wells Fargo & Company increased their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. JMP Securities reiterated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Royal Bank of Canada dropped their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, Barclays reduced their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.